Self-reported use of pharmaceuticals among patients with irritable bowel syndrome in primary care

Journal of Managed Care Pharmacy

Volumn 14, Issue 9, 2008, Pages 870-877

  Faresjö, Åshild ^a   Grodzinsky, Ewa ^b   Johansson, Saga ^c   Wallander, Mari Ann ^d   Faresjö, Tomas ^a   Timpka, Toomas ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Department of Clinical Immunology and Transfusion Medicine   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ANALGESIC AGENT; ANTACID AGENT; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIDIARRHEAL AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BALSALAZIDE; CARDIOVASCULAR AGENT; COLAZID; CONTRACEPTIVE AGENT; GASTROINTESTINAL AGENT; HYPNOTIC SEDATIVE AGENT; LAXATIVE; MESACOL; MESALAZINE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENTASAN; PROTON PUMP INHIBITOR; RENNIE; SALAZOSULFAPYRIDINE; SPASMOLYTIC AGENT; THYROID HORMONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; FIBER; HEALTH SURVEY; HUMAN; IRRITABLE COLON; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIMARY MEDICAL CARE; QUESTIONNAIRE; SELF REPORT; SWEDEN;

EID: 57749104737     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.9.870     Document Type: Article

References (49)

1. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38(9):1569-80.
2. Mertz HR. Irritable bowel syndrome. N Engl J Med. 2003;349(22):2136-46. Available at: www.content.nejm.org/cgi/reprint/349/ 22/2136.pdf. Accessed October 20, 2008.
3. Thompson WG, Dotevall G, Drossman DA, Heaton KW, Kruis W. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int. 1989;2:92-95.
4. Drossman DA, Thompson WG, Talley NJ, Funch-Jensen P, Janssen J, Whitehead WE. Identifications of subgroups of functional gastrointestinal disorders. Gastroenterol Int. 1990;3:159-72.
5. Drossman DA. The Functional Gastrointestinal Disorders. Rome II. 2nd ed. Mclean, VA: Degnon Associates; 2000.
6. Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors: Am J Gastroenterol. 2001;96(5):1340-49.
7. Herschbach P, Henrich G, von Rad M. Psychological factors in functional gastrointestinal disorders: characteristics of the disorder or of the illness behavior? Psychosom Med. 1999;61(2):148-53.
8. Whitehead WE, Crowell MD, Robinson JC, Heller BR, Schuster MM. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut. 1992;33(6):825-30.
9. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology. 1995;109(1):40-52.
10. Mertz H, Morgan V, Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distension. Gastroenterology. 2000; 118(5):842-48.
11. Hammerle C W, Surawicz C M. Updates of treatment of irritable bowel syndrome. Word J Gastroenterol 2008;14(17):2639-49.
12. Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med. 2008;358(16): 1692-99.
13. Heymann-Mönnikes I, Arnold R, Florin I, Herda C, Melfsen S, Mönnikes H. The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol. 2000; 95(4):981-94.
14. Guthrie E, Creed F, Dawson D, Tomenson B. A randomised controlled trial of psychotherapy in patients with refractory irritable bowel syndrome. Br J Psychiatry. 1993;163:315-21.
15. Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm. 2004;10(4):299-309. Available at: www.amcp.org/data/jmcp/ Subject%20Review-299-309.pdf.
16. Dapoigny M, Dyard F, Grimaud JC, Guyot P, Ganse van E. Irritable bowel syndrome and healthcare consumption. An observational study m gastroenterological practice. Gastroenterol Clin Biol 2003;3(27):1-13.
17. Kong SC, Hurlstone DP, Pocock CY, et. al. The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol. 2005;39(9):138-41.
18. Icks A, Haastert B, Enck P, Rathman W, Giani G. Prevalence of functional bowel disorders and related health care seeking: a population-based study. Z Gastroenterol. 2002;40(3):177-83.
19. FDA News. FDA permits restricted use of Zelnorm for qualifying patients. Rockville, MD. July 27, 2007. Available at: www.fda.gov/bbs/topics/NEWS/ 2007/NEW01673.html. Accessed October 20, 2008.
20. Chang L, Chey WD, Harris L, Olden K, Surawicz C, Schoenfeld P. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and postmarketing surveillance data. Am J Gastroenterol. 2006;101(5):1069-79.
21. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med. 2000; 108(1):65-72.
22. Markowitz M, Harris W, Ricci JF, et al. Comorbid conditions in patients with irritable bowel syndrome: data from a national IBS awareness registry. Gastroenterology. 2001;120(suppl 1):105.
23. Longstreth GF, Wolde-Tsadik G. Irritable bowel-type symptoms in HMO examinees. Prevalence, demographics, and clinical correlates. Dig Dis Sci. 1993;38(9):1581-89.
24. Sperber AD, Carmel S, Atzmon Y, et al. Use of the Functional Bowel Disorder Severity Index (FBDSI) in a study of patients with the irritable bowel syndrome and fibromyalgia. Am J Gastroenterol. 2000;95(4):995-98.
25. Walker EA, Gelfand AN, Gelfand MD, Green C, Katon WJ. Chronic pelvic pain and gynecological symptoms in women with irritable bowel syndrome. J Psychosom Obstet Gynaecol. 1996;17(1):39-46.
26. Sperber AD, Carmel S, Atzmon Y, et al. The sense of coherence index and the irritable bowel syndrome. A cross-sectional comparison among irritable bowel syndrome patients with and without coexisting fibromyalgia, irritable bowel syndrome non-patients, and controls. Scand J Gastroenterol. 1999;34(3):259-63.
27. Vandvik PO, Lydersen S, Farup PG. Prevalence, comorbidity and impact of irritable bowel syndrome in Norway. Scand J Gastroenterol. 2006;41(6):650-56.
28. Faresjö Å, Grodzinsky E, Johansson S, Wallander MA, Timpka T, Åerlind I. Psychosocial factors at work and in every day life are associated with irritable bowel syndrome. Eur J Epidemiol. 2007;22(7):473-80.
29. Faresjö Å, Grodzinsky E, Johansson S, Wallander MA, Foldevi M. Patients with irritable bowel syndrome in Swedish primary care. Eur J Gen Pract. 2006;12(2):88-90.
30. Faresjö Å, Grodzinsky E, Foldevi M, Johansson S, Wallander MA. Patients with irritable bowel syndrome in primary care appear not to be heavy healthcare utilizers. Aliment Pharmacol Ther. 2006;23(6):807-14.
31. Faresjö Å, Grodzinsky E, Johansson S, Wallander MA, Timpka T, Akerlind I. A population-based case-control study of work and psychosocial problems in patients with irritable bowel syndrome - women are more seriously affected than men. Am J Gastroenterol. 2007;102(2):371-79.
32. Ware JE, Snow KK, Kosinsky M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1993.
33. McHorney CA, Ware JE Jr., Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental constructs. Med Care. 1993;31(3):247-63.
34. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-70.
35. Sveriges Officiella Statistik. Statistics-Sweden. Employment, working hours and work environment 1994-1995 [in Swedish]. Stockholm, Sweden: Statistiska Centralbyrån (SCB); 1998.
36. Swedish Drug Classification (in Swedish). Available at: www.fass.se. Accessed October 28, 2008.
37. Lacy BE, Rosemore J, Robertson D, Corbin DA, Grau M, Crowell MD. Physicians' attitudes and practices in the evaluation and treatment of irritable bowel syndrome. Scand J Gastroenterol. 2006;41(8):892-902.
38. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007,23(1):163-73.
39. Schoenfeld P. Efficacy of current drug therapies in irritable bowel syndrome: what works and does not work. Gastroenterol Clin North Am. 2005;34(2):319-35.
40. Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. Aliment Pharmacol Ther. 2006;24(2):183-205.
41. Andresen V, Camilleri M. Irritable bowel syndrome: recent and novel therapeutic approaches. Drugs. 2006;66(8):1073-88.
42. Saad RJ, Chey WD. Recent developments in the therapy of irritable bowel syndrome. Expert Opin Investig Drugs. 2008;17(2):117-30.
43. Kajander K, Myllyluoma E, Rajilić-Stojanović M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther. 2008;27(1):48-57.
44. Quigley EM. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis. 2007;8(1):2-7.
45. Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil. 2007;19(3):166-72.
46. Bellini M, Tosetti C, Costa F, et al. The general practitioner's approach to irritable bowel syndrome: from intention to practice. Dig Liver Dis. 2005;37(12):934-39.
47. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome: the view from general practice. Eur J Gastroenterol Hepatol. 1997;9(7):689-92.
48. Talley NJ. When to conduct testing in patients with suspected irritable bowel syndrome. Rev Gastroenterol Disord. 2003;3(suppl.3):S18-24.
49. Agreùs L. Rome? Manning? Who Cares? Am J Gastroenterol. 2000;95(10):2679-81.